luka

@SimScaler @swordmaster18 Bro just say the CRM

@swordmaster18 DM me if you do decent volume💪

I think end of this year there won’t be many big MRR brands left on SP Unless they are SUPER compliant which makes profitability a lot harder Now even Elare switched to the best CRM in the game Fully customisable checkout with google and apple pay⚡️

@iamtyfrankel @distortedshapes You’re a homo 😭

@distortedshapes nah, I'm good. Couldn't give less of a shit how I come off to you.

Don’t be this guy in the DMs Nobody owes you anything

@realdtthomas What is your definition of a winner

question for media buyers ripping 100k+/mo is 100 new creatives a week too much or too little for finding winners if your winning creative % is around 15-20%

@jonathanzliu @heyruchir $21 LTV isn’t possible at scale

@heyruchir LTV per subscriber is $21 so my CAC needs to be below that

just burned $1.4k on paid ads and only made ~$600 back to organic it is

@ZedNilm1 Account

if you lose your facebook ad account, momentum dies overnight campaigns paused cash flow frozen pixel data stuck scaling gone most advertisers think about protection only after they get banned by then it’s already too late so i built a simple cheat sheet with the exact system i use to protect every ad account before spending real budget how to structure business managers how to lower policy risk how to warm accounts properly how to scale without triggering reviews what mistakes silently flag you no theory just the backend setup that keeps accounts alive while spending hard rt + comment “account” and i’ll send it (follow for dm)

@zoinkmaster99 @aribk24 @grok Are you retarted

@aribk24 @grok is this true or fake?

bought my 7th house a few months ago left it vacant + forgot to turn off the water pipes froze and destroyed the house GG 100k repair bill

@calebcanales_ @ecomhasan @patwerX Is everyone in moneyspace insecure?

@ecomhasan @patwerX He’s a weird dude.

I had no intention on selling anything. There’s money made from affiliate links which I guess none of you understand 🤣 For the sake of twitter I will now be selling info. Thanks for taking the bait.

@brendanhaze How do u kno he’s doing it

Dropshippers will literally noship grandmothers and put them on a starbucks subscription but then publicly beg Harley for an unban 🤣

Idc I’m gonna listen & enjoy the new drake album

@JamesJones36544 @MattNachtrab How much have you lost on this?

@MattNachtrab To say the drug doesn't work is insane. All of the family testimonies and people asking to stay on drug..

Reason for $sava placebo out performance - Low pTau to MMSE scores Lower Death Rate on simufilam .3% vs. 1.1% in donanemab placebo - Interesting Outcome to Analyze. The RETHINK was only 12 months as compared to 18 months in the other study. I think the entire $sava simufilam placebo "out performance" for RETHINK phase 3 was based on the population having on average a lower pTau than a typical population for their MMSE scores. When the numbers are announced for the placebo pTau217 for Phase 3, I predict about 5.82 pG/mL. I think it was the screening that caused it to be lower in OL and in RETHINK. I think the outperformers in OL were based on uneducated Hispanic patients getting better at taking ADAS-Cog tests vs simufilam effectiveness in addition to the effects from low pTau217. Here is a chart of placebo donanemab with ADAS-Cog 13 1 year scores on the x and pTau217 baseline on the y. It has an R2 of .9999. Change in adas-cog13 is 100% correlated to pTau217 baseline scores. Has anyone seen other research that can prove this out? Shorts were right about the drug and it's likely match to placebo, but they never brought up the reason the performance was better than historical MMSE placebo scores. I am nearly certain the outperformance was driven by pTau217 and 181 being LOW relative to a typical MMSE in the population. I bet this is proven out in the deep analysis of the data by $sava. As for falls and other symptoms that families were reporting as improving, I do not know how to explain the one off cases, but the treatment and placebo of simufilam had the exact same Fall % leading to discontinuation. Death Rates for simufilam simufilam did have fewer deaths of .3% vs. .8% in placebo and 1.1% in donanemab. I would be interested in seeing this survival rate in the total data vs. the normal AD population. Donanemab had 1.9% of patients die on treatment and 1.1% die on placebo. Death rate by baseline pTau217 would be an interesting outcome to analyze

@realdeucer @middlemarketmac @junkbondanalyst All the replies are just retarted lol Understand chemistry = insider trading

@middlemarketmac @junkbondanalyst @lukajoviccc this guy is such a moron

1) What

@ONC187 @DividendDude_X Who gaf about yur wife

@DividendDude_X Unfortunately yes . Go to the Yuka app . Wife’s a Pharma rep/ dietitian. Is all marketing .

Celsius $CELH is simply too cheap to ignore at $25 per share… This is a long-term buying opportunity in a stock where market sentiment for it is in the gutter. I am buying shares.

Brilliant

@meechferguson @crackcobain__ Not how it works idiot

I just hate when they say they ain’t ate all day like cmon

@xbtGBH Please stop. Being racist

@zollingd @oscarjpearson Because it hurts all westerners that a serb is the goat of the game. Plus he doesn't kiss anyones ass.

@killeures @vidsoqn @ddlvidbot

the end of an era, i’ve enjoyed every single second of it